Potential of longitudinal data from single site and multi-center clinical trials for AI-research

Prof. Dr. Hans-Christoph Becker from Stanford University, a long-standing user of mint Lesion™, shares his experience of using the software in this brief interview. He talks about the reaction he received when sharing the mint report for the first time, how patients benefit from the longitudinal overview of disease, and his plans to use the structured data for AI research.

Click here or on the image above to watch the full video on YouTube.

Related Resources

Related Resources

WUSTL: Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations

In this retrospective study utilizing the mint Lesion™ software[1], researchers found that routine clinical interpretations frequently resulted in the…

A doctor pushes a lying patient into the LDCT device

Early lung cancer detection through LDCT screening as a potential way to improve patient outcomes in Germany

The establishment of a nation-wide lung cancer screening program in Germany has been a subject of considerable interest and debate among healthcare…

A screenshot of a structured report from mint Lesion™

Tumor Growth Rate Modeling: A Novel Approach to Evaluating the Efficacy of Cancer Therapies

The 2020 review of Clinical Trial Evidence Supporting US Food and Drug Administrative Approval of Novel Cancer Therapies Between 2000 and 2016…